Living Cell Technologies Limited
Living Cell Technologies Granted European Patent for Neurological Disease Product NTCELL
NTCELL targets neurological diseases such as Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis and
Huntington’s disease and Stroke
Patent based on technology of implanting encapsulated porcine choroid plexus cells
Journal of Neural Engineering publishes LCT’s latest data on therapeutic benefit of choroid plexus cell implants
20 January 2010: Sydney, Australia, Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY)
today announced that it has been granted a European patent for the use of its product NTCELL in the treatment of
degenerative neurological conditions such as Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis (MS),
Huntington’s disease and Stroke.
LCT’s European patent is based on the technology of preparing NTCELL, which are encapsulated porcine cells of the
choroid plexus of the brain. The cells release growth factors and neurotrophins, which are a range of agents that
protect and maintain the health of brain cells. NTCELL was designed to protect brain cells from disease and injury and
to enhance the natural repair mechanisms in the brain. NTCELL has the potential to restore neural cells and tissue.
The porcine choroid plexus cells are encapsulated in a seaweed-derived gel. The encapsulation protects the cells from
rejection by the immune system allowing implantation without the need for toxic anti-rejection drugs.
Dr Paul Tan, Chief Executive Officer LCT said: “At a time when we are seeing regulatory approvals in Europe and the US
for clinical trials with cell-based therapeutics in neurologic disorders, we can expect NTCELL to add significant value
to LCT. The granting of this key patent for NTCELL coincides with the publication of LCT’s most recent data on cell
therapy for neurological diseases in a leading peer review journal.”
The December 2009 issue of the Journal of Neural Engineering published LCT’s paper titled “Encapsulated living choroid
plexus cells: potential long-term treatments for central nervous system disease and trauma”, which shows that
long-lasting therapeutic implants of NTCELL may be used to treat brain disease. The new experimental data indicates that
the choroid plexus cells release neuroprotective agents including antioxidants and growth supporting factors. The
implanted cells were still alive when retrieved 6 months after implantation into the brain in animals. This publication
adds to LCT’s previously published and presented data on the beneficial effects of NTCELL implants in animal models of
Parkinson’s disease, Huntington’s disease, stroke and hearing loss caused by degeneration of the auditory nerve.
-Ends-